Sorrento Therapeutics Inc. (SRNE)

    Sorrento Therapeutics ist an der Nasdaq gelistet, Biotech, auch an verschiedenen Biotechs beteiligt.


    Einen Überblick gibt dieser Bericht:


    https://seekingalpha.com/amp/i…orrento-therapeutics-srne


    Vom Ausblick für 2019/20 her vielversprechend, leider ist wie bei Biotechs üblich der Short Interest nicht zu vernachlässigen, was allerdings auch Chancen mit sich bringen kann, bei entsprechenden Erfolgen in der Produktentwicklung, ua. gegen Parkinson und Krebs.


    Aus meiner Sicht bin ich über Obducat (S)/ Kimberly Clark auf Sorrento gestossen, wo Obducat eine NIL-Machine für einen Pilotbetrieb an KC geliefert hat, für Sofusa. Sorrento hat letztes Jahr die Sofusa-Plattform erworben, die soll neuartige, effizientere Medikamente hervorbringen, siehe hier:


    https://www.sofusa.com/


    Bei entsprechenden Erfolgen sollte bei Sorrento kursmässig eine Vervielfachung drinliegen, Garantie gibt es dafür jedoch keine!


    Kursstand am 17.04.2019: $3.89

    10-Q draussen - Schlusskurs am 16.05.2019: $3.80


    http://investors.sorrentothera…10-q/0000850261-19-000020


    18. Segment Information During the quarter ended March 31, 2019, the Company realigned its businesses into two operating and reportable segments, Sorrento Therapeutics and Scilex. The Company reports segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is the Company’s Chief Executive Officer, for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on licensing, sales and services revenue, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be Sorrento Therapeutics and Scilex based on the information used by the CODM.
    Sorrento Therapeutics. The Sorrento Therapeutics segment is organized around the Company’s Immune-Oncology therapeutic area, leveraging its proprietary G-MAB™ antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy (“CAR-T”), dimeric antigen receptor T-cell therapy (“DAR-T”), antibody drug conjugates (“ADCs”) as well as bispecific antibody approaches. Additionally, this segment also includes Sofusa®, a revolutionary drug delivery system that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy, and resiniferatoxin (“RTX”), which is a non-opioid-based neurotoxin and is currently in clinical trials for late stage cancer pain and osteoarthritis.
    Scilex. The Scilex segment is largely organized around the Company’s non-opioid pain management operations and includes the operations of Scilex and Semnur. As of March 31, 2019, revenues from the Scilex segment are exclusively derived from the sale of ZTlido® (lidocaine topical system 1.8%).
    • In October 2018, Scilex commercially launched its ZTlido® (lidocaine topical system 1.8%) product and began recognizing revenue in the fourth quarter of 2018.
    • Semnur’s SP-102 compound is the first non-opioid corticosteroid formulated as a viscous gel injection in development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. SP-102 has been awarded fast track status by the FDA. See Note 4 for further detail on the Semnur acquisition.
    The Company manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. The Company’s CODM does not regularly review asset information by reportable segment and, therefore, it does not report asset information by reportable segment. The majority of longlived assets for both segments are located in the United States.


    Allein mit RTX soll im US-Markt ein Potenzial von $5 Mrd. adressiert werden können...

    http://investors.sorrentothera…nual-b-riley-fbr-investor


    SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB Riley Investor Conference and meeting with individual investors.


    Date/Time: May 22nd, 2019 at 10:30 AM.


    Location: Beverly Hilton, Los Angeles (CA), Room 9.


    A copy of the corporate presentation will be made accessible through Sorrento’s Investors Relations website at www.sorrentotherapeutics.com.


    About Sorrento Therapeutics, Inc.


    Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).


    Sorrento's commitment to life-enhancing therapies for cancer patients and Osteoarthritis (OA) patients is also demonstrated by its effort to advance Resiniferatoxin (“RTX”), a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, ZTlido® and SP-102, a non-opioid corticosteroid gel. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients and a Phase 1b trial for OA. ZTlido®was approved by US FDA on 02/28/18. SP-102 (Semdexa™) is in Phase 3 pivotal study for the treatment of lumbar radicular pain/sciatica.


    For more information visit www.sorrentotherapeutics.com.

    Habe gar nicht gesehen, dass hier über Sorrento diskutiert wird.


    Habe auch eine Position und bin gespannt wohin die Reise mit diesem Wert so geht. Könnte richtig überraschen wenn man Geduld mitbringt!


    Kaufen in Tranchen ist ein guter Tipp!:)

    http://investors.sorrentothera…utcome-motivates-sorrento


    Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain


    Jun 10, 2019 at 7:00 AM EDT


    PDF Version


    SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a local nerve block injection for the control of neuropathic post-amputation residual limb pain in humans. A full IND package is being prepared for FDA submission in the second half of 2019.


    Declawing is the amputation of the last digit in a cat’s paws. Although currently falling out of favor, this procedure used to be commonplace. The population of “aging amputee cats” living with the sequalae of surgeries performed years ago is quite large making it a valuable “model” when looking at residual limb pain which affects about 30% of the 1.6 million American amputees, or phantom limb pain which affects up to 70% of those human patients1.


    “Chronic distal limb pain in declawed cats is common in varying degrees, especially in older cats. For some, the pain is very difficult to control and often causes limping, aggressive behavior, litter box avoidance, and decreased quality of life. I was elated that the veterinarians at ARK contacted me and showed interest in helping treat this population of cats as they don’t otherwise receive much attention. I was hopeful but still cautiously optimistic that these cats could improve and be made more comfortable. My expectations were met as both cats I treated did well during the treatment and showed improvement that lasted for months afterwards. I was initially hesitant since the treatment involved anesthesia and direct injections in the paw nerves. However, experiencing the cat’s improved demeanor and reduction in negative behavior was worth the effort. Reducing or eliminating the need for daily systemic medications positively affected not only the cat’s quality of life, but also the human-animal bond with the owner,” (Dr M, Feline Specialist, Principal Investigator).


    Nine cats that have been living for years with debilitating neuropathic post-declaw pain were included to date in the on-going ARK clinical trial. Every cat treated was considered a treatment success at Day 28, regardless of dose group, as defined by FDA Center for Veterinary Medicine guidance using a validated feline pain and behavior scale (see figure 1). No failures noted through Day 120, but only 2 cats have completed the follow-up visits so far. Andy, the cat with the longest follow-up to date, is still doing well and enjoying a much-improved quality of life 7 months after treatment (see video).


    For humans, Residual Limb Pain is a common and difficult to control condition in amputees. Often the condition is managed with the use of opioids despite the high potential for addiction and the unclear long-term clinical benefits. Delivering RTX peripherally as a nerve block just like what is done with local anesthetics, is an easy and precise technique that puts the drug exactly in the area we believe might be the most effective. Any convenient to administer non-opioid solution that could provide long-term relief to amputees and potentially reduce the use for drugs or more complex procedures in their pain control strategy, would address a clear unmet need for that patient population.


    “We are looking at RTX in cats as a good long-term pain control approach given that felines do not tolerate non-steroidal anti-inflammatory drugs well (there are no NSAIDs approved in cats for chronic use) and opioids are not a viable approach for daily at home pain control. The local nerve block as a route of administration for RTX presents numerous advantages and a convenient way for veterinarians to help their feline patients without relying on off-label chronic use of daily oral medications. Given the clear clinical benefits we have seen in cats, and confirmed in some dogs, we decided to explore the same direct nerve application approach for the RTX human clinical development program,” stated Alexis Nahama, DVM, President of Ark Animal Health and Head of the RTX program.


    “In addition to our marketed product ZTlido® (lidocaine topical system) 1.8% for postherpetic neuralgia and our Phase 3 SP-102 product for sciatica back pain, RTX provides another powerful tool in our expansive arsenal of non-opioid pain management,” added Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. “The clinical data generated by our animal health division is very exciting and motivates us to accelerate the work needed to file a human IND later this year. We hope to confirm the long-term potential of RTX in helping control residual limb pain and assess the clinical benefits in reducing phantom limb pain in people”.


    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a98449dc-9b89-416f-a9e1-2dd09cb33663


    * CSOMf. Validated Scale taking into account 3 pet owner selected parameters measured (from 1 to 5) over time. Success defined as a reduction of at least 2 in total CSOMf score compared to Day 0 with no increase in any individual activities. Two treated cat patients were followed at Day 90 and one at Day 120

    SORRENTO TO EXPLORE POTENTIAL INITIAL PUBLIC OFFERING OF SCILEX HOLDING COMPANY



    SAN DIEGO, CA, June 12th, 2019/GlobeNewswire/ -- SAN DIEGO - Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company. No decisions have been taken at this point on the structure or timing of any initial public offering, and no assurance can be given that an initial public offering will be pursued or completed.
    This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.


    .... wo Rauch ist, da ist auch Feuer... :)

    Hier ein sehr guter Bericht über SRNO


    https://seekingalpha.com/insta…orrento-therapeutics-srne


    Die Schlussfolgerung im Bericht,


    Final Thoughts


    I am only able to touch on a fraction of SRNEs business model here and Investors should know there is much more happening with the company. I feel that this is a very exciting time for SRNE as they are not only expected to report data from their lead clinical programs in the 2H19, but that their prior investments are maturing and are also expected to see major advancements in the next year. I still feel strongly that SRNE is currently undervalued and represents a unique opportunity to Investors should they be willing to take on the risk.


    Braucht halt ziemlich Nerven diese Aktie unglaublich diese Schwankungen, das ist etwas gewöhnungsbedürftig...


    Uebrigens Danke Hans, dass Du diesen Thread eröffnet hast!